Who are we?
Kamada is focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Drugs Disributed by Kamada Ltd, Israel
Corticosteroid, β2 Agonist. Beclometasone Dipropionate 100 mcg/metered dose, 200 mcg/metered dose, Formoterol Fumarate (dihydrate) 6 mcg/metered dose. INHALER.(pressurised sol. for inhal.):1×120 actuat.
Asthma: Maint. therapy for pts. 18 yrs. and above- 1, 2 inhal. ×2/d. max. dly. dose is 4 inhal. Maint. & reliever ther.: Pts. 18 yrs. and above- 1 inhal. ×2/d. max. dly. dose is 8 inhal.COPD: For pts. 18 yrs. and above- 2 inhal. ×2/d. See lit.
Asthma: Regular tmt. of asthma where use of a combin. product (inhaled corticost.&long-acting β2-agonist) is approp. Pts. not adequate. control. with inhal. corticoster. and ‘as needed’ inhal. rapid-act. beta2-agonist. Pts. already adequat. control. on both inhal. corticoster. and long-act. β2-agonist. COPD :Symptom. tmt. of pts. with severe COPD (FEV1 < 50% predicted normal) and a hist. of repeated exacerb., who have signific. sympt. despite regular ther. with long-act. bronchodilators.
Corticosteroid/Beta 2-Agonist. Beclometasone Dipropionate 200mcg/metered dose, Formoterol Fumarate 6mcg/metered dose. INHALER. (Pressurised sol. for inhal).:1×120 actuation.
Adults 18 yrs. and above:
Two inhalations twice dly.
The max. dly. dose is 4 inhalat.
Foster 200/6 should be used as mainten. therapy only. A lower strength (Foster 100/6) is available for mainten. and reliever ther.
Indicated in the regular tmt. of asthma in adult. where use of a comb. product (inhaled corticosteroid and long-act. Β2-ag.) is appropriate:
Pts. not adequate. control. with inhaled corticosteroids and 'as needed' inhaled rapid-acting Β2-agonist.
Pts. already adequat. controlled on both inhaled corticosteroids and long-act. Β2-ag. C/I: Hypersens.
Human Normal Immunoglobulin 5 g/100 ml. VIALS: 1 x 2.5 g/50 ml, 5 g/100 ml, 10
g/200 ml. Dose depend. indicat. and
pharmacokinetic/clinic. response. See lit.
Replace. ther. in: Prim. immunodefic.
variable immunodefic.); Wiskott Aldrich
syndr. Myeloma/chron. lymphocytic leuk.
with severe second.
hypogammaglobulinem and recurr.
infects. Child with congen. AIDS and
C/I: Hypersens. See lit.
Alpha 1-antitrypsin (AAT) 1 g / 50 ml. VIAL (sol. for infus.): 1 x 50 ml. I.V. use
only. 60 mg/kg bdy. wt. 1 x wkly.
Chron. augmentat./maint. ther. congen.
defic. alpha1-proteinase inhib. (Alpha1-
PI), also known as alpha1-antitrypsin
(AAT) defic. and clin. evidence
C/I: Immunoglobulin A (IgA) defic. with
antibodies against IgA. Hypersens., incl.
anaphylax. to Alpha1-PI product.
Blood Coagulant. Human Coagulation Factor VIII 250, 500, 1000 IU / vial. PWDR (I.V. INJECT.): 1+ solvent. See lit.
Tmt. and proph. bleed. in hemophil. A
(congen. factor VIII defic.) with acq. factor
Anticoagulant. Heparin Sodium 10 IU/ml, 100 IU/ml. SINGLE DOSE VIAL: 10 IU/ml; 100 IU/ml x
20 x 10 ml. See lit.
Maint. potency I.V. device. May be used
foll. initial placement of device in vein or
aft. withdrawal of blood lab. analysis.
C/I: Hypersens., severe
thrombocytopen., uncontrolled active
bleed. See lit.